Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 17/20 | 0.79 |
| ▸ | SSTR2 | P30874 | 16/20 | 0.79 |
| ▸ | SSTR3 | P32745 | 11/20 | 0.79 |
| ▸ | SSTR4 | P31391 | 10/20 | 0.79 |
| ▸ | SSTR1 | P30872 | 10/20 | 0.79 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Depreotide SCHEMBL29399302 | 1.00 | SSTR5 (0.79) | SSTR5SSTR2SSTR3SSTR4SSTR1 | |
| Depreotide SCHEMBL17136142 | 0.97 | SSTR5 (0.76) | SSTR5SSTR2SSTR3SSTR4SSTR1 | |
| Depreotide SCHEMBL29392879 | 0.87 | SSTR5 (0.62) | SSTR5SSTR2SSTR3SSTR4SSTR1 | |
| SCHEMBL24108700 | 0.82 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR4SSTR1 | |
| SCHEMBL22214904 | 0.82 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR4SSTR1 | |
| Seglitide SCHEMBL29691513 | 0.73 | SSTR5 (0.56) | SSTR5SSTR2SSTR3SSTR4SSTR1 | |
| Seglitide SCHEMBL25456114 | 0.73 | SSTR5 (0.56) | SSTR5SSTR2SSTR3SSTR4SSTR1 | |
| Seglitide SCHEMBL151244 | 0.73 | SSTR5 (0.56) | SSTR5SSTR2SSTR3SSTR4SSTR1 | |
| Seglitide SCHEMBL29392970 | 0.73 | SSTR5 (0.56) | SSTR5SSTR2SSTR3SSTR4SSTR1 | |
| Seglitide SCHEMBL242685 | 0.73 | SSTR5 (0.56) | SSTR5SSTR2SSTR3SSTR4SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1674 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-12533321-B2 | Polypeptide formulations for oral delivery | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2026-01-27 | — | — | US | claimed |
| EP-4602049-A1 | SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-08-20 | — | — | EP | claimed |
| EP-4601623-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2025-08-20 | — | — | EP | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| EP-4587439-A1 | SULFONE-SUBSTITUTED PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-07-23 | — | — | EP | claimed |
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-05-15 | — | — | US | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| WO-2025021997-A1 | NEW MAP4K1 INHIBITORS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-01-30 | — | — | WO | claimed |
| US-20060009622-A1 | Conjugates of therapeutic or cytotoxic agents and biologically active peptides | ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, THE | 2006-01-12 | — | — | US | claimed |
| EP-1592456-A1 | CONTRAST ENHANCED X-RAY PHASE IMAGING | BRACCO IMAGING S.p.A. (IT) | 2005-11-09 | — | — | EP | claimed |
| CN-1649625-A | Conjugates of therapeutic or cytotoxic agents and biologically active peptides | UNIV TULANE (US) | 2005-08-03 | — | — | CN | claimed |
| EP-1401507-A4 | STABILIZATION OF RADIONUCLIDE-CONTAINING COMPOSITIONS | SCHERING AG (DE) | 2005-02-02 | — | — | EP | claimed |
| EP-1487493-A2 | CONJUGATES OF THERAPEUTIC OR CYTOTOXIC AGENTS AND BIOLOGICALLY ACTIVE PEPTIDES | The Administrators of The Tulane Educational Fund (US) | 2004-12-22 | — | — | EP | claimed |
| WO-2004071535-A1 | CONTRAST ENHANCED X-RAY PHASE IMAGING | BRACCO IMAGING S.P.A. (IT) | 2004-08-26 | — | — | WO | claimed |
| EP-1401507-A2 | STABILIZATION OF RADIONUCLIDE-CONTAINING COMPOSITIONS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-03-31 | — | — | EP | claimed |
| WO-2003074551-A2 | CONJUGATES OF THERAPEUTIC OR CYTOTOXIC AGENTS AND BIOLOGICALLY ACTIVE PEPTIDES | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2003-09-12 | — | — | WO | claimed |
| US-20020187099-A1 | Stabilization of radionuclide-containing compositions | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-12-12 | — | — | US | claimed |
| WO-2002092005-A2 | STABILIZATION OF RADIONUCLIDE-CONTAINING COMPOSITIONS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-11-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | KRAS, NRAS, TP53 | SSTR5 4362/4885SSTR2 4568/4885SSTR3 4487/4885 |
| US-12533321-B2 | Polypeptide formulations for oral delivery | PTMS, IAPP, IGF1R | SSTR5 85/4885SSTR2 327/4885SSTR3 354/4885 |
| US-20060009622-A1 | Conjugates of therapeutic or cytotoxic agents and biologically active peptides | MCL1, DNPEP, TP53 | SSTR5 1479/4885SSTR2 2717/4885SSTR3 1311/4885 |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | GLP1R, TTR, IAPP | SSTR5 23/4885SSTR2 75/4885SSTR3 130/4885 |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | MEN1, MYO1G, IL2 | SSTR5 111/4885SSTR2 264/4885SSTR3 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.